Tiprelestat Versus Placebo When Added to Standard of Care for the Treatment of Pulmonary Arterial Hypertension (PAH)

The primary objective of this study is to compare the efficacy, safety, and tolerability of tiprelestat plus Standard of Care (SOC) compared with placebo plus SOC in patients with World Health Organization (WHO) functional class II-IV pulmonary arterial hypertension (PAH).

NCT Number	NCT07601295
Lead Sponsor	Stanford University Collaborators: National Heart, Lung, and Blood Institute (NHLBI), University of Michigan
Conditions	Pulmonary Arterial Hypertension (PAH)
Enrollment	90 participants
Start Date	2026-07
Primary Completion	2030-02 (estimated)
Study Completion	2030-03 (estimated)
Updated on ClinicalTrials.gov	2026-05-22